Filing Details

Accession Number:
0001209191-23-003855
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-18 19:05:19
Reporting Period:
2023-01-13
Accepted Time:
2023-01-18 19:05:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1787400 Nkarta Inc. NKTX Pharmaceutical Preparations (2834) 474515206
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1959742 David Shook C/O Nkarta, Inc.
6000 Shoreline Court, Suite 102
South San Francisco CA 94080
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-13 37,500 $0.00 60,477 No 4 A Direct
Common Stock Disposition 2023-01-17 175 $5.49 60,302 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2023-01-13 75,000 $0.00 75,000 $5.57
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
75,000 2033-01-12 No 4 A Direct
Footnotes
  1. Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2024. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
  2. Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a discretionary transaction by the Reporting Person.
  3. This transaction was executed in multiple trades at prices ranging from $5.49 to $5.56. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2023.